Dube Eric M 4
4 · Travere Therapeutics, Inc. · Filed Oct 30, 2025
Insider Transaction Report
Form 4
Dube Eric M
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-10-28$15.46/sh+92,872$1,435,801→ 512,045 total - Sale
Common Stock
2025-10-29$30.12/sh−27,128$817,074→ 419,173 total - Exercise/Conversion
Employee stock option (right to buy)
2025-10-28−92,872→ 207,128 totalExercise: $15.46Exp: 2030-01-31→ Common Stock (92,872 underlying) - Exercise/Conversion
Common Stock
2025-10-29$15.46/sh+27,128$419,399→ 446,301 total - Exercise/Conversion
Employee stock option (right to buy)
2025-10-29−27,128→ 180,000 totalExercise: $15.46Exp: 2030-01-31→ Common Stock (27,128 underlying) - Sale
Common Stock
2025-10-28$30.38/sh−92,872$2,821,358→ 419,173 total
Footnotes (4)
- [F1]This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- [F2]The weighted average sale price for the transaction reported was $30.379, and the range of prices were between $30.00 and $30.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]The weighted average sale price for the transaction reported was $30.1192, and the range of prices were between $30.00 and $30.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F4]The stock option is fully vested and exercisable.